Alnylam Pharmaceuticals (ALNY) is lower today, extending weakness after a high-profile analyst reset: Jefferies downgraded the stock to Hold from Buy and slashed its price target to $330 from $522, arguing the shares are effectively “priced to perfection.” The call flagged risk that longer-term expectations embedded in the share price—especially around market size and competitive dynamics—may be too optimistic, limiting near-term upside and encouraging investors to lock in gains. (investing.com)

The downgrade centers less on an immediate product or trial surprise and more on what investors are already paying for future growth. Jefferies highlighted that near-term transthyretin (TTR) metrics appear achievable, but warned that consensus longer-term TTR expectations look vulnerable, leaving the stock exposed if uptake, competition, or pipeline readouts fail to exceed already-strong assumptions. (investing.com)

Traders will be watching for follow-through from other analysts (target cuts or rating changes), any incremental company updates that refine revenue trajectory for Alnylam’s TTR franchise, and the next set of pipeline milestones that could either validate the premium valuation or reinforce the idea that the market is discounting too much too soon. With the downgrade’s new $330 target close to recent trading levels, near-term price action may be especially headline- and sentiment-driven. (investing.com)